MannKind plunges 37% on Q4 earnings miss despite revenue beat
R&D and administrative costs surge 148% and 144% respectively, driven by scPharma acquisition and Afrezza pediatric launch
MannKind Corporation shares tumbled 37% to $3.50 in Thursday's extended session after the biopharmaceutical company reported fourth-quarter results that dramatically missed analyst expectations, despite delivering a revenue beat that highlighted the complexity of its ongoing strategic transformation.
The company reported adjusted earnings per share of $0.01, falling 70% short of the consensus estimate of $0.0333. More strikingly, MannKind swung to a net loss of $15.9 million for the quarter, compared with a $7.4 million profit in the same period last year.
Revenue of $112 million topped analyst projections by 39.5%, but the top-line performance was overshadowed by explosive growth in operating expenses. Research and development costs surged 148%, while selling, general, and administrative expenses climbed 144%, driven primarily by integration costs related to the scPharma acquisition and preparations for the pediatric launch of Afrezza, the company's flagship inhaled insulin therapy.
The steep decline represents a significant reversal for MannKind, which had been trading near its 52-week high of $6.51 earlier this year. Thursday's selloff pushed the stock toward its yearly low of $3.29, wiping out approximately $960 million in market capitalization and leaving the company valued at roughly $1.56 billion.
Analysts remain broadly optimistic about MannKind's long-term prospects, with eight Buy ratings and one Strong Buy among covering firms, and an average price target of $9.44—nearly 170% above current levels. However, the earnings miss raises questions about the timeline to profitability as the company absorbs the costs of its expansion strategy.
According to regulatory filings, the scPharma acquisition—completed last year—provides MannKind with additional drug delivery technology platforms and expanded manufacturing capabilities. Meanwhile, the pediatric launch of Afrezza represents a significant commercial opportunity, as it would open a new patient population for the therapy, which has primarily been prescribed to adult patients with diabetes.
The disconnect between revenue growth and profitability highlights a common challenge for biopharmaceutical companies in the expansion phase: the substantial upfront investments required to build commercial infrastructure and secure regulatory approvals for new indications often outpace near-term revenue gains.
Full-year 2025 results painted a more positive picture, with annual revenue growth of 17.2% year-over-year and total revenue of $313.8 million. However, quarterly earnings growth declined 34.9%, underscoring the increasing cost pressures the company faces as it scales operations.
MannKind management is scheduled to host an earnings call Friday morning to provide additional color on the company's 2026 guidance and updated timeline for achieving profitability. Investors will be particularly focused on management's projections for when the increased investments in R&D and commercial infrastructure will begin to translate into sustainable earnings growth.
The steep post-earnings decline reflects Wall Street's impatience with companies prioritizing growth over profitability in the current interest rate environment, where the cost of capital remains elevated and investors have grown increasingly selective about funding expansion strategies that lack clear paths to near-term returns.